340 related articles for article (PubMed ID: 18524797)
1. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly.
Holdaway IM; Bolland MJ; Gamble GD
Eur J Endocrinol; 2008 Aug; 159(2):89-95. PubMed ID: 18524797
[TBL] [Abstract][Full Text] [Related]
2. GH and mortality in acromegaly.
Sheppard MC
J Endocrinol Invest; 2005; 28(11 Suppl International):75-7. PubMed ID: 16625851
[TBL] [Abstract][Full Text] [Related]
3. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
[TBL] [Abstract][Full Text] [Related]
4. IGF-I and mortality in patients with acromegaly.
Strasburger CJ
J Endocrinol Invest; 2005; 28(11 Suppl International):78-80. PubMed ID: 16625852
[TBL] [Abstract][Full Text] [Related]
5. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
[TBL] [Abstract][Full Text] [Related]
6. [Growth hormone (GH) and IGF-I assays: methodological aspects and its implications in acromegaly diagnosis and follow-up].
Casagrande A; Czepielewski MA
Arq Bras Endocrinol Metabol; 2007 Jun; 51(4):511-9. PubMed ID: 17684610
[TBL] [Abstract][Full Text] [Related]
7. Dynamic tests and basal values for defining active acromegaly.
Tzanela M
Neuroendocrinology; 2006; 83(3-4):200-4. PubMed ID: 17047383
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.
Freda PU; Post KD; Powell JS; Wardlaw SL
J Clin Endocrinol Metab; 1998 Nov; 83(11):3808-16. PubMed ID: 9814451
[TBL] [Abstract][Full Text] [Related]
9. Monitoring disease activity using GH and IGF-I in the follow-up of 501 patients with acromegaly.
Sherlock M; Aragon Alonso A; Reulen RC; Ayuk J; Clayton RN; Holder G; Sheppard MC; Bates A; Stewart PM
Clin Endocrinol (Oxf); 2009 Jul; 71(1):74-81. PubMed ID: 19178529
[TBL] [Abstract][Full Text] [Related]
10. The critical parameters in GH excess.
Sheppard MC
J Endocrinol Invest; 2005; 28(5 Suppl):92-5. PubMed ID: 16114283
[TBL] [Abstract][Full Text] [Related]
11. Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 and urinary growth hormone excretion.
Bates AS; Evans AJ; Jones P; Clayton RN
Clin Endocrinol (Oxf); 1995 Apr; 42(4):417-23. PubMed ID: 7750196
[TBL] [Abstract][Full Text] [Related]
12. Thyroid vascularity is increased in patients with active acromegaly.
Bogazzi F; Manetti L; Bartalena L; Gasperi M; Grasso L; Cecconi E; Rago T; Pinchera A; Martino E
Clin Endocrinol (Oxf); 2002 Jul; 57(1):65-70. PubMed ID: 12100071
[TBL] [Abstract][Full Text] [Related]
13. Excess mortality in acromegaly.
Holdaway IM
Horm Res; 2007; 68 Suppl 5():166-72. PubMed ID: 18174739
[TBL] [Abstract][Full Text] [Related]
14. Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic.
Mercado M; Gonzalez B; Vargas G; Ramirez C; de los Monteros AL; Sosa E; Jervis P; Roldan P; Mendoza V; López-Félix B; Guinto G
J Clin Endocrinol Metab; 2014 Dec; 99(12):4438-46. PubMed ID: 25210882
[TBL] [Abstract][Full Text] [Related]
15. Size heterogeneity of circulating growth hormone in acromegaly. "Big-big" GH forms are associated with inappropriately low IGF-I levels.
Arosio M; Nissim M; Ballabio M; Orefice R; Bazzoni N; Faglia G
Acta Endocrinol (Copenh); 1991 Aug; 125(2):150-9. PubMed ID: 1897332
[TBL] [Abstract][Full Text] [Related]
16. A paradigm shift in the monitoring of patients with acromegaly: last available growth hormone may overestimate risk.
Sherlock M; Reulen RC; Aragon-Alonso A; Ayuk J; Clayton RN; Sheppard MC; Hawkins MM; Bates AS; Stewart PM
J Clin Endocrinol Metab; 2014 Feb; 99(2):478-85. PubMed ID: 24243636
[TBL] [Abstract][Full Text] [Related]
17. Serum insulin-like growth factor-binding protein-3 levels in the diagnosis of acromegaly.
Grinspoon S; Clemmons D; Swearingen B; Klibanski A
J Clin Endocrinol Metab; 1995 Mar; 80(3):927-32. PubMed ID: 7533774
[TBL] [Abstract][Full Text] [Related]
18. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy.
Peacey SR; Toogood AA; Veldhuis JD; Thorner MO; Shalet SM
J Clin Endocrinol Metab; 2001 Jan; 86(1):259-66. PubMed ID: 11232010
[TBL] [Abstract][Full Text] [Related]
19. Gender and age influence the relationship between serum GH and IGF-I in patients with acromegaly.
Parkinson C; Renehan AG; Ryder WD; O'Dwyer ST; Shalet SM; Trainer PJ
Clin Endocrinol (Oxf); 2002 Jul; 57(1):59-64. PubMed ID: 12100070
[TBL] [Abstract][Full Text] [Related]
20. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly.
Biermasz NR; van Dulken H; Roelfsema F
J Clin Endocrinol Metab; 2000 Dec; 85(12):4596-602. PubMed ID: 11134114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
